Mirador Capital Partners’s Bristol-Myers Squibb BMY Stock Holding History

Mirador Capital Partners’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.81M	Sell	48,795 -75	-0.2%	-$4.31K	0.34%	57
2026 Q1	$2.96M	Buy	48,870 +1,012	+2%	+$59K	0.42%	51
2025 Q4	$2.58M	Sell	47,858 -347	-0.7%	-$16.7K	0.35%	59
2025 Q3	$2.17M	Sell	48,205 -457	-0.9%	-$21.3K	0.31%	62
2025 Q2	$2.25M	Buy	48,662 +496	+1%	+$24.3K	0.37%	52
2025 Q1	$2.94M	Buy	48,166 +812	+2%	+$47.3K	0.51%	46
2024 Q4	$2.68M	Buy	47,354 +774	+2%	+$43.2K	0.49%	45
2024 Q3	$2.41M	Buy	46,580 +165	+0.4%	+$7.74K	0.43%	47
2024 Q2	$1.93M	Buy	46,415 +931	+2%	+$41.7K	0.36%	46
2024 Q1	$2.47M	Buy	45,484 +1,889	+4%	+$96.2K	0.47%	50
2023 Q4	$2.24M	Buy	43,595 +1,106	+3%	+$58.1K	0.47%	52
2023 Q3	$2.47M	Buy	42,489 +990	+2%	+$60.7K	0.56%	46
2023 Q2	$2.65M	Buy	41,499 +80	+0.2%	+$5.36K	0.63%	48
2023 Q1	$2.87M	Sell	41,419 -1,532	-4%	-$108K	0.68%	41
2022 Q4	$3.09M	Sell	42,951 -356	-0.8%	-$26.8K	0.73%	34
2022 Q3	$3.08M	Buy	43,307 +412	+1%	+$29.9K	0.74%	36
2022 Q2	$3.3M	Buy	42,895 +639	+2%	+$48.7K	0.78%	37
2022 Q1	$3.09M	Buy	42,256 +2,450	+6%	+$165K	0.62%	44
2021 Q4	$2.48M	Buy	39,806 +999	+3%	+$58.6K	0.52%	53
2021 Q3	$2.3M	Buy	38,807 +744	+2%	+$49K	0.52%	52
2021 Q2	$2.54M	Buy	38,063 +1,128	+3%	+$73.6K	0.58%	53
2021 Q1	$2.33M	Buy	36,935 +1,858	+5%	+$116K	0.6%	55
2020 Q4	$2.18M	Buy	35,077 +3,420	+11%	+$210K	0.6%	54
2020 Q3	$1.91M	Sell	31,657 -11,557	-27%	-$696K	0.6%	51
2020 Q2	$2.54M	Buy	43,214 +480	+1%	+$28.7K	0.95%	32
2020 Q1	$2.61M	Buy	42,734 +3,848	+10%	+$235K	1.09%	28
2019 Q4	$2.5M	Buy	38,886 +137	+0.4%	+$7.85K	1.01%	30
2019 Q3	$1.97M	Buy	38,749 +647	+2%	+$30.4K	0.88%	38
2019 Q2	$1.73M	Buy	38,102 +3,257	+9%	+$152K	0.85%	44
2019 Q1	$1.66M	Sell	34,845 -463	-1%	-$23.1K	0.9%	39
2018 Q4	$1.83M	Sell	35,308 -667	-2%	-$35.8K	1.13%	31
2018 Q3	$2.23M	Buy	35,975 +885	+3%	+$52.5K	1.09%	28
2018 Q2	$1.94M	Buy	35,090 +8	+0%	+$432	1.06%	33
2018 Q1	$1.83M	Sell	35,082 -18,347	-34%	-$1.18M	1.28%	27
2017 Q4	$3.27M	Sell	53,429 -160	-0.3%	-$10K	1.79%	16
2017 Q3	$3.46M	Buy	53,589 +218	+0.4%	+$12.7K	2.03%	11
2017 Q2	$2.99M	Sell	53,371 -2,559	-5%	-$139K	1.83%	13
2017 Q1	$3.04M	Buy	55,930 +7,205	+15%	+$395K	2.21%	10
2016 Q4	$2.85M	Buy	48,725 +14,618	+43%	+$799K	2.28%	7
2016 Q3	$1.84M	Buy	34,107 +3,229	+10%	+$207K	1.62%	17
2016 Q2	$2.31M	Sell	30,878 -2,381	-7%	-$168K	2.32%	10
2016 Q1	$2.13M	Buy	+33,259	New	+$2.1M	2.36%	8

Other funds holding BMY

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

DLA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

ETC

Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Mirador Capital Partners's BMY Position: Q2 2026 in Review

Mirador Capital Partners reduced its Bristol-Myers Squibb (BMY) stake by 0.15% in Q2 2026, selling an estimated $4.31K and leaving 48,795 shares worth $2.81M. The position accounts for 0.34% of the portfolio, ranked #57.

Mirador Capital Partners first reported a position in BMY in Q1 2016 and has held it in 42 quarters since. The position peaked at $3.46M in Q3 2017. 878 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Mirador Capital Partners held 48,795 shares of Bristol-Myers Squibb worth $2.81M as of Q2 2026.
Mirador Capital Partners sold 75 Bristol-Myers Squibb shares in Q2 2026, an estimated $4.31K.
Bristol-Myers Squibb made up 0.34% of Mirador Capital Partners's portfolio in Q2 2026, its #57 holding.
Mirador Capital Partners first reported a position in Bristol-Myers Squibb in Q1 2016 and has held it in 42 quarters since.
Mirador Capital Partners's Bristol-Myers Squibb position peaked at $3.46M in Q3 2017.
878 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Mirador Capital Partners's 13F filing for Q2 2026, filed 7 Jul 2026.